Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

BACKGROUND: OnabotulinumtoxinA is effective in preventing chronic migraine (CM); however, the benefit of onabotulinumtoxinA in patients with CM with daily headache is unknown because these patients are typically excluded from clinical trials. This subanalysis of the COMPEL Study assessed the efficac...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Headache Pain
Главные авторы: Young, William B., Ivan Lopez, J., Rothrock, John F., Orejudos, Amelia, Manack Adams, Aubrey, Lipton, Richard B., Blumenfeld, Andrew M.
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Milan 2019
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6734507/
https://ncbi.nlm.nih.gov/pubmed/30709333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-018-0953-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы